Collectively, our results uncover a novel ARF6‐PI3K/AKT/mTOR signaling axis that drives AML progression, suggesting that targeting this pathway may represent a promising therapeutic strategy for this challenging malignancy. This evidence concerns the gene MTOR and acute myeloid leukemia.